百濟神州有限公司

  • 英文名稱:BeiGene Ltd
  • 網址:https://www.beigene.com/
  • 社群網址
  • 股票代號:6160.HK、688235.SH、BGNE.US
  • 發展階段:上市

產業領域

A02西藥製劑(新藥開發)、C06再生醫療(細胞治療、基因治療、組織工程等)

公司簡介

百濟神州有限公司是一家中國生物技術公司,有蘇州和廣州兩家生產基地。百濟神州成立於2010年10月28日,總部位於中國北京市,為一家商業階段的生物技術公司,專注於開發及商業化用於治療癌症的創新型分子靶向及腫瘤免疫治療藥物,2018年8月8日於香港聯交所上市,2021年12月15日於上海證交所科創板上市。 BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. Currently employees are located in APAC, Americas, and Europe. BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients. BeiGene continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our passionate interest in fighting cancer.

相關文章